Literature DB >> 12643178

Is hepatic glucose production increased in type 2 diabetes mellitus?

Henning Beck-Nielsen1, Ole Hother-Nielsen, Peter Staehr.   

Abstract

Based on recent studies, including our own, using what we consider to be an appropriate technique to estimate rates of hepatic glucose production (HGP), this article can be summarized as follows: 1) HGP in the overnight fasted state is near normal in obese type 2 diabetes (T2D) subjects, i.e., it may be increased by a mean of 12% compared to matched control subjects. 2) Suppression of HGP by insulin shows a rightward shift of the dose response curve (reduced insulin sensitivity) but normal maximal suppression (no maximum velocity defect). 3) In the overnight fasted state, gluconeogenesis is responsible for two thirds of HGP in T2D subjects and is about 5% to 10% increased compared to healthy subjects. 4) Suppression of HGP during a meal is close to normal. 5) The slightly increased HGP values throughout the 24-hour period together with reduced metabolic clearance rate (peripheral insulin resistance) and increased carbohydrate intake is responsible for the increase in fasting plasma glucose values. 6) Hypothetically, the role of the liver in nondiabetic and T2D subjects may be to produce the amount of glucose needed for metabolism in peripheral tissues. If insulin-mediated glucose uptake in skeletal muscle is reduced, plasma glucose will increase due to the "nonsuppressed" HGP values. Plasma glucose continues to rise until glucose-mediated glucose uptake compensates completely for the reduction in insulin-mediated glucose uptake.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12643178     DOI: 10.1007/s11892-002-0088-0

Source DB:  PubMed          Journal:  Curr Diab Rep        ISSN: 1534-4827            Impact factor:   4.810


  26 in total

Review 1.  Banting Lecture 1997. Control of glucose uptake and release by the liver in vivo.

Authors:  A D Cherrington
Journal:  Diabetes       Date:  1999-05       Impact factor: 9.461

2.  Undiagnosed NIDDM: clinical and public health issues.

Authors:  M I Harris
Journal:  Diabetes Care       Date:  1993-04       Impact factor: 19.112

3.  Assessment of hepatic insulin action in obese type 2 diabetic patients.

Authors:  P Staehr; O Hother-Nielsen; K Levin; J J Holst; H Beck-Nielsen
Journal:  Diabetes       Date:  2001-06       Impact factor: 9.461

4.  Contributions by kidney and liver to glucose production in the postabsorptive state and after 60 h of fasting.

Authors:  K Ekberg; B R Landau; A Wajngot; V Chandramouli; S Efendic; H Brunengraber; J Wahren
Journal:  Diabetes       Date:  1999-02       Impact factor: 9.461

5.  Production and metabolic clearance of glucose under basal conditions in Type II (non-insulin-dependent) diabetes mellitus.

Authors:  J Radziuk; S Pye
Journal:  Diabetologia       Date:  2001-08       Impact factor: 10.122

6.  Evidence for a major role of skeletal muscle lipolysis in the regulation of lipid oxidation during caloric restriction in vivo.

Authors:  E Hagström-Toft; A Thörne; S Reynisdottir; E Moberg; S Rössner; J Bolinder; P Arner
Journal:  Diabetes       Date:  2001-07       Impact factor: 9.461

7.  Quantitative contributions of gluconeogenesis to glucose production during fasting in type 2 diabetes mellitus.

Authors:  A Wajngot; V Chandramouli; W C Schumann; K Ekberg; P K Jones; S Efendic; B R Landau
Journal:  Metabolism       Date:  2001-01       Impact factor: 8.694

8.  Modeling error and apparent isotope discrimination confound estimation of endogenous glucose production during euglycemic glucose clamps.

Authors:  D T Finegood; R N Bergman; M Vranic
Journal:  Diabetes       Date:  1988-08       Impact factor: 9.461

9.  Relationship between hepatic glucose production and fasting plasma glucose concentration in patients with NIDDM.

Authors:  C Y Jeng; W H Sheu; M M Fuh; Y D Chen; G M Reaven
Journal:  Diabetes       Date:  1994-12       Impact factor: 9.461

Review 10.  The fourth musketeer--from Alexandre Dumas to Claude Bernard.

Authors:  G M Reaven
Journal:  Diabetologia       Date:  1995-01       Impact factor: 10.122

View more
  8 in total

1.  Temporal profiling of the transcriptional basis for the development of corticosteroid-induced insulin resistance in rat muscle.

Authors:  Richard R Almon; Debra C Dubois; Jin Y Jin; William J Jusko
Journal:  J Endocrinol       Date:  2005-01       Impact factor: 4.286

2.  Deletion of CaMKK2 from the liver lowers blood glucose and improves whole-body glucose tolerance in the mouse.

Authors:  Kristin A Anderson; Fumin Lin; Thomas J Ribar; Robert D Stevens; Michael J Muehlbauer; Christopher B Newgard; Anthony R Means
Journal:  Mol Endocrinol       Date:  2012-01-12

Review 3.  Insulin resistance in Alzheimer's disease.

Authors:  Thomas Diehl; Roger Mullins; Dimitrios Kapogiannis
Journal:  Transl Res       Date:  2016-12-13       Impact factor: 7.012

4.  Clinical implications of canagliflozin treatment in patients with type 2 diabetes.

Authors:  Virginia Valentine; Deborah Hinnen
Journal:  Clin Diabetes       Date:  2015-01

5.  Correcting Postprandial Hyperglycemia in Zucker Diabetic Fatty Rats With an SGLT2 Inhibitor Restores Glucose Effectiveness in the Liver and Reduces Insulin Resistance in Skeletal Muscle.

Authors:  Tracy P O'Brien; Erin C Jenkins; Shanea K Estes; Antonio V Castaneda; Kiichiro Ueta; Tiffany D Farmer; Allison E Puglisi; Larry L Swift; Richard L Printz; Masakazu Shiota
Journal:  Diabetes       Date:  2017-02-28       Impact factor: 9.461

Review 6.  Metabolic Adaptation in Obesity and Type II Diabetes: Myokines, Adipokines and Hepatokines.

Authors:  Kyoung-Jin Oh; Da Som Lee; Won Kon Kim; Baek Soo Han; Sang Chul Lee; Kwang-Hee Bae
Journal:  Int J Mol Sci       Date:  2016-12-22       Impact factor: 5.923

7.  Pathophysiology of Type 2 Diabetes in Children and Adolescents.

Authors:  Badhma Valaiyapathi; Barbara Gower; Ambika P Ashraf
Journal:  Curr Diabetes Rev       Date:  2020

Review 8.  The Association of Acute Phase Proteins in Stress and Inflammation-Induced T2D.

Authors:  Tammy Speelman; Lieke Dale; Ann Louw; Nicolette J D Verhoog
Journal:  Cells       Date:  2022-07-11       Impact factor: 7.666

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.